Valbenazine Treatment of Tardive Dyskinesia and of Positive Symptoms
- 18 October 2021
- journal article
- letter
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 42 (1) , 109-111
Abstract
An abstract is unavailable. This article is available as a PDF only.Keywords
This publication has 7 references indexed in Scilit:
- Case ReportJournal of Clinical Psychopharmacology, 2021
- A long-term, open-label study of valbenazine for tardive dyskinesiaCNS Spectrums, 2020
- Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic actionPharmacology Biochemistry and Behavior, 2020
- Pharmacologic Characterization of Valbenazine (NBI-98854) and Its MetabolitesThe Journal of Pharmacology and Experimental Therapeutics, 2017
- Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for DiseasePharmacological Reviews, 2015
- NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled studyMovement Disorders, 2015
- Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy-Confirmed Dementia With Lewy BodiesAmerican Journal of Psychiatry, 2004